Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
5,450.00
0.00 (0.00%)
At close: Jun 5, 2025, 3:30 PM KST
Kyongbo Pharmaceutical Revenue
Kyongbo Pharmaceutical had revenue of 60.59B KRW in the quarter ending March 31, 2025, a decrease of -3.21%. This brings the company's revenue in the last twelve months to 236.54B, up 2.40% year-over-year. In the year 2024, Kyongbo Pharmaceutical had annual revenue of 238.56B with 10.26% growth.
Revenue (ttm)
236.54B
Revenue Growth
+2.40%
P/S Ratio
0.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
130.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 238.56B | 22.20B | 10.26% |
Dec 31, 2023 | 216.36B | 20.09B | 10.24% |
Dec 31, 2022 | 196.26B | 25.61B | 15.00% |
Dec 31, 2021 | 170.66B | -44.63B | -20.73% |
Dec 31, 2020 | 215.29B | 23.58B | 12.30% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 146.42B |